Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses

References

• Carmelo S, Richard HH. (2008). Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 8:677–84
   PubMed Web of Science ®Google Scholar
• Chen M, Ma L, Drusano GL, et al (2006). Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 80:531–8
   PubMed Web of Science ®Google Scholar
• Cho H, Choi MK, Cho DY, et al (2012). Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol 52:976–84
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Giacchino M, et al (2013). The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opin Drug Metab Toxicol 9:1361–9
   PubMed Web of Science ®Google Scholar
• Du YQ, Guo WY, Zou DW, et al (2012). Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis 13:113–19
   PubMed Web of Science ®Google Scholar
• Freston JW, Pilmer BL, Chiu YL, et al (2004). Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Ther 19:1111–12
   PubMed Web of Science ®Google Scholar
• Holster IL, Kuipers EJ. (2011). Update on the endoscopic management of peptic ulcer bleeding. Curr Gastroenterol Rep 13:525–31
   PubMedGoogle Scholar
• Ho KY, Kuan A, Zano F, et al (2009). Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. J Gastroenterol 44:697–707
   PubMed Web of Science ®Google Scholar
• Hummel J, McKendrick S, Brindley C, et al (2009). Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8:38–49
   PubMed Web of Science ®Google Scholar
• Hu ZY, Zhao YS. (2010). Sex-dependent differences in cytochrome P450 3A activity as assessed by Midazolam disposition in humans: a meta-analysis. Drug Metab Dispos 38:817–23
   PubMed Web of Science ®Google Scholar
• Kim EJ, Lee RK, Lee SM, et al (2001). General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung 51:51–9
   PubMed Web of Science ®Google Scholar
• Kwon D, Chae JB, Park CW, et al (2001). Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung 51:204–13
   PubMed Web of Science ®Google Scholar
• Laine L, Jensen DM. (2012). Management of patients with ulcer bleeding. Am J Gastroenterol 107:345–60
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang W, Guo D, et al (2008). Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 391:60–7
   PubMed Web of Science ®Google Scholar
• Lima-Oliveira G, Salvagno GL, Danese E, et al (2015). Sodium citrate blood contamination by K2 -ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing. Int J Lab Hematol 37:403–9
   PubMed Web of Science ®Google Scholar
• Myung SW, Min HK, Jin C. (1999). Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res 22:189–93
   PubMed Web of Science ®Google Scholar
• Periclou AP, Goldwater R, Lee SM, et al (2000). A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 68:304–11
   PubMed Web of Science ®Google Scholar
• Robinson M. (2004). The pharmacodynamics and pharmacokinetics of proton pumpinhibitors–overview and clinical implications. Aliment Pharmacol Ther 20:1–10
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. (2006). The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23:2–8
   Web of Science ®Google Scholar
• Saitoh T, Watanabe Y, Kubo Y, et al (2001). Intragastric acidity and circadian rhythm. Biomed Pharmacother 55:138–41
   Web of Science ®Google Scholar
• Schneider H, van Rensburg C, Schmidt S, et al (2004). Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 70:250–6
   PubMed Web of Science ®Google Scholar
• Seo KA, Lee SJ, Kim KB, et al (2012). Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica 42:278–84
   PubMed Web of Science ®Google Scholar
• Shin JS, Lee JY, Cho KH, et al (2014). The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. Aliment Pharmacol Ther 40:548–61
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. (2008). Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935–51
   PubMed Web of Science ®Google Scholar
• Smith BP, Vandenhende FR, DeSante KA, et al (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–83
   PubMed Web of Science ®Google Scholar
• Sung JJ, Chan FK, Chen M, et al (2011). Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding. Gut 60:1170–7
   PubMed Web of Science ®Google Scholar
• Sung JJ, Suen BY, Wu JC, et al (2014). Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Am J Gastroenterol 109:1005–10
   PubMed Web of Science ®Google Scholar
• Taubel JJ, Sharma VK, Chiu YL, et al (2001). A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-hour intragastric pH. Aliment Pharmacol Ther 15:1807–17
   PubMed Web of Science ®Google Scholar
• van Herwaarden MA, Samsom M, Smout AJ. (1999). 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl 230:9–16
   PubMedGoogle Scholar
• Wang L, Zhou L, Hu H, et al (2012). Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin 28:101–9
   PubMed Web of Science ®Google Scholar
• Wang J, Yang K, Ma B, et al (2009). Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Can J Gastroenterol 23:287–99
   PubMed Web of Science ®Google Scholar
• Yu G, Lu XQ, Su RB, et al (2014). Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats. Dig Dis Sci 59:2417–22
   PubMed Web of Science ®Google Scholar
• Yüksel I, Ataseven H, Köklü S, et al (2008). Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study. Digestion 78:39–43
   PubMed Web of Science ®Google Scholar
• Zhou G, Shi S, Zhang W, et al (2010). Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed Chromatogr 24:1130–5
   PubMed Web of Science ®Google Scholar